Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial-Reference-Cited by-同舟云学术

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

Published:2012-08 Issue:8 Volume:13 Page:773-781
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Infante Jeffrey R,Fecher Leslie A,Falchook Gerald S,Nallapareddy Sujatha,Gordon Michael S,Becerra Carlos,DeMarini Douglas J,Cox Donna S,Xu Yanmei,Morris Shannon R,Peddareddigari Vijay GR,Le Ngocdiep T,Hart Lowell,Bendell Johanna C,Eckhardt Gail,Kurzrock Razelle,Flaherty Keith,Burris Howard A,Messersmith Wells A

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. Development of anticancer drugs targeting the MAP kinase pathway;Sebolt-Leopold;Oncogene,2000

2. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy;Fremin;J Hematol Oncol,2010

3. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer;Roberts;Oncogene,2007

4. A synthetic inhibitor of the mitogen-activated protein kinase cascade;Dudley;Proc Natl Acad Sci USA,1995

5. MAP kinase pathway signalling is essential for extracellular matrix determined mammary epithelial cell survival;Finlay;Cell Death Differ,2000

Cited by 475 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation;Cells;2024-09-09

2. Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel inKRAS-mutated colorectal cancer;2024-09-06

3. Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients;Cancers;2024-08-07

4. A combination of the geroprotectors trametinib and rapamycin is more effective than either drug alone;2024-07-25

5. Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage;Journal of Biomedical Science;2024-07-11